Merrimack Pharmaceuticals Inc. buy marge
Zusammenfassung
Diese Einschätzung wurde am 08.07.16 mit einem Endkurs von 51,41 € beendet. Abwärts ging es seit Start der Einschätzung mit Merrimack Pharmaceuticals Inc.. Verglichen mit dem Start ergibt sich eine Rendite von -16,30 %. marge hat 50% Zuversicht bei dieser EinschätzungRendite ohne Dividenden (%)
| Name | 1W | 1M | 1J | 3J |
|---|---|---|---|---|
| Merrimack Pharmaceuticals Inc. | - | - | - | - |
| iShares Core DAX® | 2,75 % | 4,62 % | 17,12 % | 21,21 % |
| iShares Nasdaq 100 | 0,47 % | -0,33 % | 37,78 % | 57,86 % |
| iShares Nikkei 225® | -2,93 % | -5,56 % | 12,18 % | 8,41 % |
| iShares S&P 500 | 0,68 % | 0,63 % | 29,00 % | 48,20 % |
Kommentare von marge zu dieser Einschätzung
In der Diskussion Merrimack Pharmaceuticals Inc. diskutieren
FDA genehmigt: Die Behandlung von Patienten mit metastasiertem Bauchspeicheldrüsenkrebs!
A speculative pick of the bunch with a small biotech concern called Merrimack Pharmaceuticals, which is at under $7.00 a share, about half its levels earlier this summer. The stock has declined despite the fact the FDA approved Merrimack's main drug candidate MM-398 known by its brand name "Onivyde" , in combination with fluorouracil and leucovorin, for the treatment of patients with metastatic pancreatic cancer who have been previously treated with gemcitabine-based chemotherapy in late October. Onivyde could eventually have $800 million in annual sales which is about equal to Merrimack's current market capitalization.
The company also has several promising compounds "MM-121, MM-141, MM-302" or "shots on goal" in early and mid-stage development as well. Merrimack recently raised $175 million to fund development of these drugs.
Four analysts have price targets on Merrimack in a relatively tight range of $13.00 to $15.00 a share.